# Karius

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/karius

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.kariusdx.com/
- Total disclosed funding: $330M
- Latest round: Series C (May 2, 2024)
- Investors on record: 14

## About

Based in California, US, and founded in 2014 by co-founders Mickey Kertesz, Ph.D., and Tim Blauwkamp, Karius, Inc. operates as a life sciences company that focuses on the treatment of infectious diseases. In May 2024, Karius, Inc. raised USD 100 million in Series C funding co-led by 5AM Ventures, Gilde Healthcare Partners, and Khosla Ventures, with participation from Seventure, Blue Water Life Science Advisors, General Catalyst Partners, HBM Partners, SB Investment Advisers, and Waycross Ventures. As of 2024, the company is led by its CEO, Alec Ford.

The company provides a wide range of diagnostic products, such as the Karius Test, a microbial liquid biopsy for infectious diseases. Additionally, the firm also provides services such as clinical metagenomic next-generation sequencing (mNGS) and AI-driven analysis for rapid pathogen detection and treatment optimization.

## Funding rounds

- Series C, May 2, 2024, $100M — General Catalyst Partners, HBM Partners, Seventure Partners, Gilde Healthcare, 5AM Ventures, Khosla Ventures, Innovation Endeavors, Waycross Ventures, SB Investment Advisers, Blue Water Life Science Advisors
- Series B, Mar 7, 2022, $5M — HBM Partners
- Series B, Jan 20, 2021, $5M — HBM Partners
- Series B, Feb 14, 2020, $165M — Lightspeed Venture Partners, General Catalyst Partners, HBM Partners, Khosla Ventures, SB Investment Advisers
- Series A, Aug 7, 2017, $50M — Lightspeed Venture Partners, Khosla Ventures, Tencent Investment, Innovation Endeavors, DCVC, S28 Capital
- Seed, Sep 22, 2014, $5M — Lightspeed Venture Partners, Innovation Endeavors, DCVC

## Investors

- Lightspeed Venture Partners (https://capitalatlas.ai/funds/lightspeed-venture-partners) — Seed, Series A, Series B
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Seed, Series A, Series C
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed, Series A
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Series A, Series B, Series C
- Tencent Investment — Series A
- S28 Capital (https://capitalatlas.ai/funds/s28-capital) — Series A
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B, Series C
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B, Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series B, Series C
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series C
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series C
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series C
- Waycross Ventures — Series C
- Blue Water Life Science Advisors (https://capitalatlas.ai/funds/blue-water-life-science-advisors) — Series C